Cobenfy (Xanomeline Tart/Trospium Chlor) Patent Expiration, LOE Window & CMS Spending

Cobenfy (Xanomeline Tart/Trospium Chlor) by Bristol Myers Squibb: FDA Orange Book LOE 2039-10-29, 0 AB generics, $3.8M 2024 CMS Part D & Medicaid spend, and $3,145 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN216158 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-10-29
Orange Book Patents (*PED Extensions)11 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$3.8M
2024 Medicare Part D Spend$2.4M
2024 Medicaid Spend$1.5M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,145 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.